Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study

IntroductionPemetrexed is approved as a single agent for advanced and metastatic thymoma and thymic carcinoma. In practice, pemetrexed is often given with carboplatin, but the safety and effectiveness of this combination has not been established in either of these rare diseases.MethodsWe identified...

Description complète

Détails bibliographiques

Auteurs principaux:	Benjamin A. Bleiberg, Lauren Reed-Guy, Roger B. Cohen, Charu Aggarwal, Corey J. Langer, Aditi P. Singh, Melina E. Marmarelis
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2026-04-01
Collection:	Frontiers in Oncology
Sujets:	carboplatin chemotherapy clinical outcomes pemetrexed retrospective study thymic carcinoma
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1795920/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!